期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 61, 期 7, 页码 2989-3007出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00068
关键词
-
资金
- Department of Defense CDMRP BCRP [W81XWH-14-1-0083]
- NIH [P30-CA76292]
Structure-based optimization was conducted to improve the potency, selectivity, and cell-based activities of beta-catenin/B-cell lymphoma 9 (BCL9) inhibitors based on the 4'-fluoro-N-phenyl-[1,1'-biphenyl]-3-carboxamide scaffold, which was designed to mimic the side chains of the hydrophobic a-helical hot spots at positions i, i + 3, and i + 7. Compound 29 was found to disrupt the beta-catenin/BCL9 protein-protein interaction (PPI) with a K-i of 0.47 mu M and >1900-fold selectivity for beta-catenin/BCL9 over beta-catenin/E-cadherin PPIs. The proposed binding mode of new inhibitors was consistent with the results of site-directed mutagenesis and structure-activity relationship studies. Cell-based studies indicated that 29 disrupted the beta-catenin/BCL9 interaction without affecting the beta-catenin/E-cadherin interaction, selectively suppressed transactivation of Wnt/beta-catenin signaling, downregulated expression of Wnt target genes, and inhibited viability of Wnt/beta-catenin-dependent cancer cells in dose-dependent manners. A comparison of the biochemical and cell-based assay results offered the directions for future inhibitor optimization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据